News

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of a respected leader in science, technology, and sustainability, Patricia Verduin, PhD, ...

What is CMT-SORD? In 2019, with Charcot-Marie-Tooth Association (CMTA) funding, researchers discovered CMT-SORD. CMTA Alliance Partner, Applied Therapeutics, then quickly identified a drug which they successfully tested in a newly CMTA-developed CMT-SORD model before rapidly advancing into the current Phase III ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of health insurance industry veteran Wendy Arnone to its Board of Directors. ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $450K into a new scientific approach for CMT1A and CMT1B, two common forms of the disease. ...

Charcot-Marie-Tooth Association (CMTA) Alliance Partner, NMD Pharma, announced the publication of comprehensive data sets demonstrating for the first time the ability of CIC-1 inhibition to restore muscle function in patients suffering from neuromuscular junction (NMJ) transmission deficits. These data are ...